Arkolith/Insider Trading/AVIR/Form 4

Sommadossi Jean-Pierre

President, CEO, and Chairman, DirectorAtea Pharmaceuticals, Inc. (AVIR) · full profile →Form 4 · filed Feb 4, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
3 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2025Grant(A)100K——390K
Jan 31, 2025Option exercise(M)173K——290K
Jan 31, 2025Tax withholding(F)89K$3.06$271K301K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2025Grant(A)440K—$0440K
Jan 31, 2025Grant(A)100K—$0100K
Jan 31, 2025Option exercise(M)173K—$0173K

Transaction Codes

A
Grant / award
M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-013846) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML